---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-119726"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2023-11-20T23:59:59+00:00"
generated_at: "2026-06-07T23:17:11.123684+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Promis Neurosciences doses first subject in Phase 1a trial of PMN310 for Alzheimer's

## Summary
- First-in-human Phase 1a study of PMN310, a monoclonal antibody selective for toxic Aβ oligomers, is underway.
- Up to 5 cohorts of 8 healthy volunteers each receive a single ascending dose; 85-day study with optional Day 120 follow-up.
- Initial safety and pharmacokinetic data expected in first half of 2024.
- Company raised >$20M in Q3 2023 private placement to support development through clinical milestones.
- CEO Gail Farfel highlights transition to clinical stage and potential differentiation from other AD treatments.

## SEC filing metadata
- accession: 0001104659-23-119726
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2023-11-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000110465923119726/0001104659-23-119726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000110465923119726/tm2331130d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-119726
- JSON: https://secwatch.observer/filing/0001104659-23-119726.json
- Plain text: https://secwatch.observer/filing/0001104659-23-119726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.